A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

Exclusion Criteria

• •Colorectal adenocarcinoma that is RAS mutant or for which RAS mutation status is unknown
• •Known active central nervous system metastases and/or carcinomatous meningitis; leptomeningeal disease
• •Immunodeficiency or active autoimmune disease requiring systemic treatment in the past 2 years
• •Presence of acute or chronic pancreatitis
• •Clinically significant cardiovascular diseases (eg, thromboembolic or cerebrovascular accident events ≤ 12 wks prior)
• •Received a live or live-attenuated vaccine within 30 days of planned start of study medication
• •Previous treatment with any selective BRAF inhibitor (eg, encorafenib, dabrafenib, vemurafenib, XL281/BMS-908662) or any epidermal growth factor receptor (EGFR) inhibitor (eg, cetuximab, panitumumab).
• •Previous treatment with an immune checkpoint inhibitor (eg, anti-programmed cell death \[PD-1\], anti-PD-L1 or anti-PD-L2 agent); or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).